| 000 | 00906 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518081648.0 | ||
| 264 | 0 | _c20200123 | |
| 008 | 202001s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(19)32594-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiang, Fei | |
| 245 | 0 | 0 |
_aOptimising first-line treatment for metastatic renal cell carcinoma. _h[electronic resource] |
| 260 |
_bLancet (London, England) _c01 2020 |
||
| 300 |
_ae8 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aCarcinoma, Renal Cell |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKidney Neoplasms |
| 650 | 0 | 4 | _aSunitinib |
| 773 | 0 |
_tLancet (London, England) _gvol. 395 _gno. 10219 _gp. e8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(19)32594-2 _zAvailable from publisher's website |
| 999 |
_c30534919 _d30534919 |
||